Animal models of schizophrenia

Current Topics in Behavioral Neurosciences

Volumn 4, Issue , 2010, Pages 391-433

  Young, Jared W ^a   Zhou, Xianjin ^a   Geyer, Mark A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CATECHOL METHYLTRANSFERASE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; DISRUPTED IN SCHIZOPHRENIA 1 PROTEIN; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DYSBINDIN; GLUTAMATE RECEPTOR ANTAGONIST; HALOPERIDOL; NEU DIFFERENTIATION FACTOR; NEUROLEPTIC AGENT; OLANZAPINE; PHENCYCLIDINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SEROTONIN AGONIST; SERTINDOLE; TRANSCRIPTION FACTOR SP4;

ARTICLE; ATTENTION DISTURBANCE; CHOLINERGIC SYSTEM; CHRNA7 GENE; CHROMOSOME DELETION 15Q13.3; CHROMOSOME DELETION 22Q11; COGNITIVE DEFECT; COMT GENE; CONSTRUCT VALIDITY; COPY NUMBER VARIATION; DISEASE MODEL; DISRUPTED IN SCHIZOPHRENIA 1 GENE; DTNBP1 GENE; ENVIRONMENTAL FACTOR; ETIOLOGICAL VALIDITY; EXECUTIVE FUNCTION; FACE VALIDITY; GENE; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC MODEL; GENETIC SUSCEPTIBILITY; HALLUCINATION; LATENT INHIBITION; NEGATIVE SYNDROME; NEUREGULIN 1 GENE; NONHUMAN; NPAS3 GENE; POSITIVE SYNDROME; PREDICTIVE VALIDITY; PREPULSE INHIBITION; PRIORITY JOURNAL; SCHIZOPHRENIA; SELF STIMULATION; SENSORY GATING; SEROTONINERGIC SYSTEM; SP4 GENE; TRANSGENIC MOUSE; VALIDITY; VISUAL MEMORY; WORKING MEMORY;

EID: 84862890417     PISSN: 18663370     EISSN: 18663389     Source Type: Book Series    
DOI: 10.1007/7854_2010_62     Document Type: Article

References (260)

1. Abdul-Monim Z, Reynolds GP, Neill JC (2006) The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behav Brain Res 169:263-273
2. Abdul-Monim Z, Neill JC, Reynolds GP (2007) Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. J Psychopharmacol 21:198-205
3. Adams B, Moghaddam B (1998) Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci 18:5545-5554
4. Akhondzadeh S, Gerami M, Noroozian M, Karamghadiri N, Ghoreishi A, Abbasi SH, Rezazadeh SA (2008) A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 32:1810-1815
5. Amitai N, Semenova S, Markou A (2007) Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats. Psychopharmacology (Berl) 193:521-537
6. Amitai N, Semenova S, Markou A (2009) Clozapine attenuates disruptions in response inhibition and task efficiency induced by repeated phencyclidine administration in the intracranial selfstimulation procedure. Eur J Pharmacol 602:78-84
7. Anastasio NC, Johnson KM (2008) Differential regulation of the NMDA receptor by acute and sub-chronic phencyclidine administration in the developing rat. J Neurochem 104:1210-1218
8. Andreasen NC, Flaum M, Schultz S, Duzyurek S, Miller D (1997) Diagnosis, methodology and subtypes of schizophrenia. Neuropsychobiology 35:61-63
9. Arinami T (2006) Analyses of the associations between the genes of 22q11 deletion syndrome and schizophrenia. J Hum Genet 51:1037-1045
10. Baddeley AD (1986) Working memory. Oxford University Press, Oxford
11. Barak S (2009) Modeling cholinergic aspects of schizophrenia: focus on the antimuscarinic syndrome. Behav Brain Res 204:335-451
12. Barch DM, Carter CS, Arnsten A, Buchanan RW, Cohen JD, Geyer M, Green MF, Krystal JH, Nuechterlein K, Robbins T, Silverstein S, Smith EE, Strauss M, Wykes T, Heinssen R (2009) Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting. Schizophr Bull 35:109-214
13. Barense MD, Fox MT, Baxter MG (2002) Aged rats are impaired on an attentional set-shifting task sensitive to medial frontal cortex damage in young rats. Learn Mem 9:191-201
14. Barr AM, Phillips AG (1999) Withdrawal following repeated exposure to d-amphetamine decreases responding for a sucrose solution as measured by a progressive ratio schedule of reinforcement. Psychopharmacology (Berl) 141:99-106
15. Barr AM, Zis AP, Phillips AG (2002) Repeated electroconvulsive shock attenuates the depressivelike effects of d-amphetamine withdrawal on brain reward function in rats. Psychopharmacology (Berl) 159:196-202
16. Baruch I, Hemsley DR, Gray JA (1988) Differential performance of acute and chronic schizophrenics in a latent inhibition task. J Nerv Ment Dis 176:598-606
17. Bassett AS, Marshall CR, Lionel AC, Chow EW, Scherer SW (2008) Copy number variations and risk for schizophrenia in 22q11.2 deletion syndrome. Hum Mol Genet 17:4045-4053
18. Birrell JM, Brown VJ (2000) Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci 20:4320-4324
19. Bissonette GB, Martins GJ, Franz TM, Harper ES, Schoenbaum G, Powell EM (2008) Double dissociation of the effects of medial and orbital prefrontal cortical lesions on attentional and affective shifts in mice. J Neurosci 28:1124-1130
20. Blackwood DH, Fordyce A, Walker MT, St Clair DM, Porteous DJ, Muir WJ (2001) Schizophrenia and affective disorders-cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. Am J Hum Genet 69:428-433
21. Braff DL, Geyer MA (1990) Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry 47:181-188
22. Braff D, Stone C, Callaway E, Geyer M, Glick I, Bali L (1978) Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 15:339-343
23. Brigman JL, Ihne J, Saksida LM, Bussey TJ, Holmes A (2009) Effects of subchronic phencyclidine (PCP) treatment on social behaviors, and operant discrimination and reversal learning in C57BL/6J mice. Front Behav Neurosci 3:2
24. Brunskill EW, Witte DP, Shreiner AB, Potter SS (1999) Characterization of npas3, a novel basic helix-loop-helix PAS gene expressed in the developing mouse nervous system. Mech Dev 88:237-241
25. Buchanan RW, Freedman R, Javitt DC, Abi-Dargham A, Lieberman JA (2007) Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull 33:1120-1130
26. Bushnell PJ, Kelly KL, Crofton KM (1994) Effects of toluene inhalation on detection of auditory signals in rats. Neurotoxicol Teratol 16:149-160
27. Callicott JH, Straub RE, Pezawas L, Egan MF, Mattay VS, Hariri AR, Verchinski BA, Meyer-Lindenberg A, Balkissoon R, Kolachana B, Goldberg TE, Weinberger DR (2005) Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Proc Natl Acad Sci USA 102:8627-8632
28. Cannon M, Jones P (1996) Schizophrenia. J Neurol Neurosurg Psychiatry 60:604-613
29. Cannon TD, Hennah W, van Erp TG, Thompson PM, Lonnqvist J, Huttunen M, Gasperoni T, Tuulio-Henriksson A, Pirkola T, Toga AW, Kaprio J, Mazziotta J, Peltonen L (2005) Association of DISC1/TRAX haplotypes with schizophrenia, reduced prefrontal gray matter, and impaired short-and long-term memory. Arch Gen Psychiatry 62:1205-1213
30. Carli M, Robbins TW, Evenden JL, Everitt BJ (1983) Effects of lesions to ascending noradrenergic neurones on performance of a 5-choice serial reaction task in rats; implications for theories of dorsal noradrenergic bundle function based on selective attention and arousal. Behav Brain Res 9:361-380
31. Carter CJ (2006) Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability. Schizophr Res 86:1-14
32. Carter CS, Barch DM (2007) Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative. Schizophr Bull 33:1131-1137
33. Chen KC, Baxter MG, Rodefer JS (2004a) Central blockade of muscarinic cholinergic receptors disrupts affective and attentional set-shifting. Eur J Neurosci 20:1081-1088
34. Chen X, Wang X, O'Neill AF, Walsh D, Kendler KS (2004b) Variants in the catechol-omethyltransferase (COMT) gene are associated with schizophrenia in Irish high-density families. Mol Psychiatry 9:962-967
35. Chen YJ, Johnson MA, Lieberman MD, Goodchild RE, Schobel S, Lewandowski N, Rosoklija G, Liu RC, Gingrich JA, Small S, Moore H, Dwork AJ, Talmage DA, Role LW (2008) Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components. J Neurosci 28:6872-6883
36. Christakou A, Robbins TW, Everitt BJ (2001) Functional disconnection of a prefrontal corticaldorsal striatal system disrupts choice reaction time performance: implications for attentional function. Behav Neurosci 115:812-825
37. Chudasama Y, Robbins TW (2004) Psychopharmacological approaches to modulating attention in the five-choice serial reaction time task: implications for schizophrenia. Psychopharmacology (Berl) 174:86-98
38. Clapcote SJ, Lipina TV, Millar JK, Mackie S, Christie S, Ogawa F, Lerch JP, Trimble K, Uchiyama M, Sakuraba Y, Kaneda H, Shiroishi T, Houslay MD, Henkelman RM, Sled JG, Gondo Y, Porteous DJ, Roder JC (2007) Behavioral phenotypes of Disc1 missense mutations in mice. Neuron 54:387-402
39. Connolly PM, Maxwell C, Liang Y, Kahn JB, Kanes SJ, Abel T, Gur RE, Turetsky BI, Siegel SJ (2004) The effects of ketamine vary among inbred mouse strains and mimic schizophrenia for the P80, but not P20 or N40 auditory ERP components. Neurochem Res 29:1179-1188
40. Corfas G, Roy K, Buxbaum JD (2004) Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia. Nat Neurosci 7:575-580
41. Cornblatt B, Obuchowski M, Schnur DB, O'Brien JD (1997) Attention and clinical symptoms in schizophrenia. Psychiatr Q 68:343-359
42. Cornblatt B, Obuchowski M, Schnur D, O'Brien JD (1998) Hillside study of risk and early detection in schizophrenia. Br J Psychiatry Suppl 172:26-32
43. Cosgrove J, Newell TG (1991) Recovery of neuropsychological functions during reduction in use of phencyclidine. J Clin Psychol 47:159-169
44. Cox MM, Tucker AM, Tang J, Talbot K, Richer DC, Yeh L, Arnold SE (2009) Neurobehavioral abnormalities in the dysbindin-1 mutant, sandy, on a C57BL/6J genetic background. Genes Brain Behav 8:390-397
45. Davis KL, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148:1474-1486
46. Deller T, Sarter M (1998) Effects of repeated administration of amphetamine on behavioral vigilance: evidence for "sensitized" attentional impairments. Psychopharmacology (Berl) 137:410-414
47. Diaz-Asper CM, Goldberg TE, Kolachana BS, Straub RE, Egan MF, Weinberger DR (2008) Genetic variation in catechol-O-methyltransferase: effects on working memory in schizophrenic patients, their siblings, and healthy controls. Biol Psychiatry 63:72-79
48. Didriksen M, Skarsfeldt T, Arnt J (2007) Reversal of PCP-induced learning and memory deficits in the Morris' water maze by sertindole and other antipsychotics. Psychopharmacology (Berl) 193:225-233
49. Dudchenko PA (2004) An overview of the tasks used to test working memory in rodents. Neurosci Biobehav Rev 28:699-709
50. Dudchenko PA, Wood ER, Eichenbaum H (2000) Neurotoxic hippocampal lesions have no effect on odor span and little effect on odor recognition memory but produce significant impairments on spatial span, recognition, and alternation. J Neurosci 20:2964-2977
51. Dyer MA, Freudenreich O, Culhane MA, Pachas GN, Deckersbach T, Murphy E, Goff DC, Evins AE (2008) High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophr Res 102:88-95
52. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, Goldman D, Weinberger DR (2001) Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 98:6917-6922
53. Egerton A, Reid L, McKerchar CE, Morris BJ, Pratt JA (2005) Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia. Psychopharmacology (Berl) 179:77-84
54. Eisener A, Pato MT, Medeiros H, Carvalho C, Pato CN (2007) Genetics of schizophrenia: recent advances. Psychopharmacol Bull 40:168-177
55. Ellenbroek BA, Cools AR (2000) Animal models for the negative symptoms of schizophrenia. Behav Pharmacol 11:223-233
56. Erlenmeyer-Kimling L (2000) Neurobehavioral deficits in offspring of schizophrenic parents: liability indicators and predictors of illness. Am J Med Genet 97:65-71
57. Fagerlund B, Soholm B, Fink-Jensen A, Lublin H, Glenthoj BY (2007) Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study. Clin Neuropharmacol 30:3-12
58. Falls DL (2003) Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 284:14-30
59. Farrow TF, Hunter MD, Haque R, Spence SA (2006) Modafinil and unconstrained motor activity in schizophrenia: double-blind crossover placebo-controlled trial. Br J Psychiatry 189:461-462
60. Ferreri F, Agbokou C, Gauthier S (2006) Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy. J Psychiatry Neurosci 31:369-376
61. Fletcher PJ, Tenn CC, Rizos Z, Lovic V, Kapur S (2005) Sensitization to amphetamine, but not PCP, impairs attentional set shifting: reversal by a D1 receptor agonist injected into the medial prefrontal cortex. Psychopharmacology (Berl) 183:190-200
62. Fletcher PJ, Tenn CC, Sinyard J, Rizos Z, Kapur S (2007) A sensitizing regimen of amphetamine impairs visual attention in the 5-choice serial reaction time test: reversal by a D1 receptor agonist injected into the medial prefrontal cortex. Neuropsychopharmacology 32:1122-1132
63. Floresco SB, Geyer MA, Gold LH, Grace AA (2005) Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia. Schizophr Bull 31:888-894
64. Freedman B, Chapman LJ (1973) Early subjective experience in schizophrenic episodes. J Abnorm Psychol 82:46-54
65. Freedman R, Adler LE, Bickford P, Byerley W, Coon H, Cullum CM, Griffith JM, Harris JG, Leonard S, Miller C et al (1994) Schizophrenia and nicotinic receptors. Harv Rev Psychiatry 2:179-192
66. Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A, Polymeropoulos M, Holik J, Hopkins J, Hoff M, Rosenthal J, Waldo MC, Reimherr F, Wender P, Yaw J, Young DA, Breese CR, Adams C, Patterson D, Adler LE, Kruglyak L, Leonard S, Byerley W (1997) Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA 94:587-592
67. Gao XM, Sakai K, Roberts RC, Conley RR, Dean B, Tamminga CA (2000) Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry 157:1141-1149
68. Geyer MA (2006) The family of sensorimotor gating disorders: comorbitities or diagnostic overlaps. Neurotox Res 10:211-220
69. Geyer MA, Braff DL (1987) Startle habituation and sensorimotor gating in schizophrenia and related animal models. Schizophr Bull 13:643-668
70. Geyer MA, Markou A (1995) Animal models of psychiatric disorders. In: Bloom FE, Kupfer D (eds) Psychopharmacology: the fourth generation of progress. Raven Press, New York, pp 787-798
71. Geyer MA, Vollenweider FX (2008) Serotonin research: contributions to understanding psychoses. Trends Pharmacol Sci 29:445-453
72. Geyer MA, Russo PV, Masten VL (1986) Multivariate assessment of locomotor behavior: pharmacological and behavioral analyses. Pharmacol Biochem Behav 25:277-288
73. Geyer MA, Braff D, Swerdlow NR (1999) Startle-response measures of information processing in animals. In: Haug M, Whalen RE (eds) Animal models of human emotion & cognition. APA Books, Washington, DC, pp 103-116
74. Gisquet-Verrier P, Delatour B (2006) The role of the rat prelimbic/infralimbic cortex in working memory: not involved in the short-term maintenance but in monitoring and processing functions. Neuroscience 141:585-596
75. Goetghebeur P, Dias R (2009) Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat-a back translational study. Psychopharmacology (Berl) 202:287-293
76. Goldberg TE, Weinberger DR (1995) Thought disorder, working memory and attention: interrelationships and the effects of neuroleptic medications. Int Clin Psychopharmacol 10(Suppl 3):99-104
77. Gottesman II, Erlenmeyer-Kimling L (2001) Family and twin strategies as a head start in defining prodromes and endophenotypes for hypothetical early-interventions in schizophrenia. Schizophr Res 51:93-102
78. Gouzoulis-Mayfrank E, Habermeyer E, Hermle L, Steinmeyer A, Kunert H, Sass H (1998) Hallucinogenic drug induced states resemble acute endogenous psychoses: results of an empirical study. Eur Psychiatry 13:399-406
79. Gray NS, Snowden RJ (2005) The relevance of irrelevance to schizophrenia. Neurosci Biobehav Rev 29:989-999
80. Grayson B, Idris NF, Neill JC (2007) Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav Brain Res 184:31-38
81. Greco B, Invernizzi RW, Carli M (2005) Phencyclidine-induced impairment in attention and response control depends on the background genotype of mice: reversal by the mGLU(2/3) receptor agonist LY379268. Psychopharmacology (Berl) 179:68-76
82. GreenMF (1996)What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153:321-330
83. Green MF (2006a) Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 67(Suppl 9):3-8, discussion 36-42
84. Green MF (2006b) Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 67:e12
85. Green MF, Marder SR, Glynn SM, McGurk SR, Wirshing WC, Wirshing DA, Liberman RP, Mintz J (2002) The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry 51:972-978
86. Green EK, Raybould R, Macgregor S, Gordon-Smith K, Heron J, Hyde S, Grozeva D, Hamshere M, Williams N, Owen MJ, O'Donovan MC, Jones L, Jones I, Kirov G, Craddock N (2005) Operation of the schizophrenia susceptibility gene, neuregulin 1, across traditional diagnostic boundaries to increase risk for bipolar disorder. Arch Gen Psychiatry 62:642-648
87. Grottick AJ, Higgins GA (2000) Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task. Behav Brain Res 117:197-208
88. Hagan JJ, Jones DN (2005) Predicting drug efficacy for cognitive deficits in schizophrenia. Schizophr Bull 31:830-853
89. Harrison PJ, Law AJ (2006) Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry 60:132-140
90. Hattori S, Murotani T, Matsuzaki S, Ishizuka T, Kumamoto N, Takeda M, Tohyama M, Yamatodani A, Kunugi H, Hashimoto R (2008) Behavioral abnormalities and dopamine reductions in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia. Biochem Biophys Res Commun 373:298-302
91. He J, Xu H, Yang Y, Rajakumar D, Li X, Li XM (2006) The effects of chronic administration of quetiapine on the phencyclidine-induced reference memory impairment and decrease of Bcl-XL/Bax ratio in the posterior cingulate cortex in rats. Behav Brain Res 168:236-242
92. Hennah W, Tuulio-Henriksson A, Paunio T, Ekelund J, Varilo T, Partonen T, Cannon TD, Lonnqvist J, Peltonen L (2005) A haplotype within the DISC1 gene is associated with visual memory functions in families with a high density of schizophrenia. Mol Psychiatry 10:1097-1103
93. Hennah W, Thomson P, McQuillin A, Bass N, Loukola A, Anjorin A, Blackwood D, Curtis D, Deary IJ, Harris SE, Isometsa ET, Lawrence J, Lonnqvist J, Muir W, Palotie A, Partonen T, Paunio T, Pylkko E, Robinson M, Soronen P, Suominen K, Suvisaari J, Thirumalai S, St Clair D, Gurling H, Peltonen L, Porteous D (2009) DISC1 association, heterogeneity and interplay in schizophrenia and bipolar disorder. Mol Psychiatry 14:865-873
94. Hikida T, Jaaro-Peled H, Seshadri S, Oishi K, Hookway C, Kong S, Wu D, Xue R, Andrade M, Tankou S, Mori S, Gallagher M, Ishizuka K, Pletnikov M, Kida S, Sawa A (2007) Dominantnegative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proc Natl Acad Sci USA 104:14501-14506
95. Hodges DB Jr, Lindner MD, Hogan JB, Jones KM, Markus EJ (2009) Scopolamine induced deficits in a battery of rat cognitive tests: comparisons of sensitivity and specificity. Behav Pharmacol 20:237-251
96. Hodgkinson CA, Goldman D, Jaeger J, Persaud S, Kane JM, Lipsky RH, Malhotra AK (2004) Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. Am J Hum Genet 75:862-872
97. Horrobin DF (1998) Schizophrenia: the illness that made us human. Med Hypotheses 50:269-288
98. Hoyle E, Genn RF, Fernandes C, Stolerman IP (2006) Impaired performance of alpha7 nicotinic receptor knockout mice in the five-choice serial reaction time task. Psychopharmacology (Berl) 189:211-223
99. Humby T, Laird FM, Davies W, Wilkinson LS (1999) Visuospatial attentional functioning in mice: interactions between cholinergic manipulations and genotype. Eur J Neurosci 11: 2813-2823
100. Hurlemann R, Matusch A, Kuhn KU, Berning J, Elmenhorst D, Winz O, Kolsch H, Zilles K, Wagner M, Maier W, Bauer A (2008) 5-HT2A receptor density is decreased in the at-risk mental state. Psychopharmacology (Berl) 195:579-590
101. Ishizuka K, Chen J, Taya S, Li W, Millar JK, Xu Y, Clapcote SJ, Hookway C, Morita M, Kamiya A, Tomoda T, Lipska BK, Roder JC, Pletnikov M, Porteous D, Silva AJ, Cannon TD, Kaibuchi K, Brandon NJ, Weinberger DR, Sawa A (2007) Evidence that many of the DISC1 isoforms in C57BL/6J mice are also expressed in 129S6/SvEv mice. Mol Psychiatry 12:897-899
102. Javitt DC, Liederman E, Cienfuegos A, Shelley AM (1999) Panmodal processing imprecision as a basis for dysfunction of transient memory storage systems in schizophrenia. Schizophr Bull 25:763-775
103. Jentsch JD, Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20: 201-225
104. Jentsch JD, Redmond DE Jr, Elsworth JD, Taylor JR, Youngren KD, Roth RH (1997) Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 277:953-955
105. Jones CK, Eberle EL, Shaw DB, McKinzie DL, Shannon HE (2005) Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats. J Pharmacol Exp Ther 312:1055-1063
106. Jones DNC, Garlton JE, Minassian A, Perry W, Geyer MA (2008) Developing new drigs for schizophrenia: From animals to the clinic. In: McArthur R, Borsini F (eds) Animal and reductions in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia. Biochem Biophys Res Commun 373:298-302
107. He J, Xu H, Yang Y, Rajakumar D, Li X, Li XM (2006) The effects of chronic administration of quetiapine on the phencyclidine-induced reference memory impairment and decrease of Bcl-XL/Bax ratio in the posterior cingulate cortex in rats. Behav Brain Res 168:236-242
108. Hennah W, Tuulio-Henriksson A, Paunio T, Ekelund J, Varilo T, Partonen T, Cannon TD, Lonnqvist J, Peltonen L (2005) A haplotype within the DISC1 gene is associated with visual memory functions in families with a high density of schizophrenia. Mol Psychiatry 10:1097-1103
109. Hennah W, Thomson P, McQuillin A, Bass N, Loukola A, Anjorin A, Blackwood D, Curtis D, Deary IJ, Harris SE, Isometsa ET, Lawrence J, Lonnqvist J, Muir W, Palotie A, Partonen T, Paunio T, Pylkko E, Robinson M, Soronen P, Suominen K, Suvisaari J, Thirumalai S, St Clair D, Gurling H, Peltonen L, Porteous D (2009) DISC1 association, heterogeneity and interplay in schizophrenia and bipolar disorder. Mol Psychiatry 14:865-873
110. Hikida T, Jaaro-Peled H, Seshadri S, Oishi K, Hookway C, Kong S, Wu D, Xue R, Andrade M, Tankou S, Mori S, Gallagher M, Ishizuka K, Pletnikov M, Kida S, Sawa A (2007) Dominantnegative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proc Natl Acad Sci USA 104:14501-14506
111. Hodges DB Jr, Lindner MD, Hogan JB, Jones KM, Markus EJ (2009) Scopolamine induced deficits in a battery of rat cognitive tests: comparisons of sensitivity and specificity. Behav Pharmacol 20:237-251
112. Hodgkinson CA, Goldman D, Jaeger J, Persaud S, Kane JM, Lipsky RH, Malhotra AK (2004) Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. Am J Hum Genet 75:862-872
113. Horrobin DF (1998) Schizophrenia: the illness that made us human. Med Hypotheses 50:269-288
114. Hoyle E, Genn RF, Fernandes C, Stolerman IP (2006) Impaired performance of alpha7 nicotinic receptor knockout mice in the five-choice serial reaction time task. Psychopharmacology (Berl) 189:211-223
115. Humby T, Laird FM, Davies W, Wilkinson LS (1999) Visuospatial attentional functioning in mice: interactions between cholinergic manipulations and genotype. Eur J Neurosci 11: 2813-2823
116. Hurlemann R, Matusch A, Kuhn KU, Berning J, Elmenhorst D, Winz O, Kolsch H, Zilles K, Wagner M, Maier W, Bauer A (2008) 5-HT2A receptor density is decreased in the at-risk mental state. Psychopharmacology (Berl) 195:579-590
117. Ishizuka K, Chen J, Taya S, Li W, Millar JK, Xu Y, Clapcote SJ, Hookway C, Morita M, Kamiya A, Tomoda T, Lipska BK, Roder JC, Pletnikov M, Porteous D, Silva AJ, Cannon TD, Kaibuchi K, Brandon NJ, Weinberger DR, Sawa A (2007) Evidence that many of the DISC1 isoforms in C57BL/6J mice are also expressed in 129S6/SvEv mice. Mol Psychiatry 12:897-899
118. Javitt DC, Liederman E, Cienfuegos A, Shelley AM (1999) Panmodal processing imprecision as a basis for dysfunction of transient memory storage systems in schizophrenia. Schizophr Bull 25:763-775
119. Jentsch JD, Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20: 201-225
120. Jentsch JD, Redmond DE Jr, Elsworth JD, Taylor JR, Youngren KD, Roth RH (1997) Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 277:953-955
121. Jones CK, Eberle EL, Shaw DB, McKinzie DL, Shannon HE (2005) Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats. J Pharmacol Exp Ther 312:1055-1063
122. Jones DNC, Garlton JE, Minassian A, Perry W, Geyer MA (2008) Developing new drigs for schizophrenia: From animals to the clinic. In: McArthur R, Borsini F (eds) Animal and Animal Models of Schizophrenia 425 translational models for CNS drug discovery: psychiatric disorders. Elsevier Inc., New York, pp 199-262
123. Kamnasaran D, Muir WJ, Ferguson-Smith MA, Cox DW (2003) Disruption of the neuronal PAS3 gene in a family affected with schizophrenia. J Med Genet 40:325-332
124. Karayiorgou M, Gogos JA, Galke BL, Wolyniec PS, Nestadt G, Antonarakis SE, Kazazian HH, Housman DE, Pulver AE (1998) Identification of sequence variants and analysis of the role of the catechol-O-methyl-transferase gene in schizophrenia susceptibility. Biol Psychiatry 43:425-431
125. Kato T, Iwamoto K, Kakiuchi C, Kuratomi G, Okazaki Y (2005) Genetic or epigenetic difference causing discordance between monozygotic twins as a clue to molecular basis of mental disorders. Mol Psychiatry 10:622-630
126. Keller JJ, Keller AB, Bowers BJ, Wehner JM (2005) Performance of alpha7 nicotinic receptor null mutants is impaired in appetitive learning measured in a signaled nose poke task. Behav Brain Res 162:143-152
127. Kendler KS, Diehl SR (1993) The genetics of schizophrenia: a current, genetic-epidemiologic perspective. Schizophr Bull 19:261-285
128. Klaning U (1999) Greater occurrence of schizophrenia in dizygotic but not monozygotic twins. Register-based study. Br J Psychiatry 175:407-409
129. Kohler CG, Martin EA, Kujawski E, Bilker W, Gur RE, Gur RC (2007) No effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia. Cogn Neuropsychiatry 12:412-421
130. Koike H, Arguello PA, Kvajo M, Karayiorgou M, Gogos JA (2006) Disc1 is mutated in the 129S6/ SvEv strain and modulates working memory in mice. Proc Natl Acad Sci USA 103:3693-3697
131. Koskinen T, Ruotsalainen S, Puumala T, Lappalainen R, Koivisto E, Mannisto PT, Sirvio J (2000) Activation of 5-HT2A receptors impairs response control of rats in a five-choice serial reaction time task. Neuropharmacology 39:471-481
132. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214
133. Kunitachi S, Fujita Y, Ishima T, Kohno M, Horio M, Tanibuchi Y, Shirayama Y, Iyo M, Hashimoto K (2009) Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: role of sigma-1 receptors. Brain Res 1279:189-196
134. Kvajo M, McKellar H, Arguello PA, Drew LJ, Moore H, MacDermott AB, Karayiorgou M, Gogos JA (2008) A mutation in mouse Disc1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition. Proc Natl Acad Sci USA 105:7076-7081
135. Lacroix L, Broersen LM, Weiner I, Feldon J (1998) The effects of excitotoxic lesion of the medial prefrontal cortex on latent inhibition, prepulse inhibition, food hoarding, elevated plus maze, active avoidance and locomotor activity in the rat. Neuroscience 84:431-442
136. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R (1999) Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 46:56-72
137. Lavedan C, Licamele L, Volpi S, Hamilton J, Heaton C, Mack K, Lannan R, Thompson A, Wolfgang CD, Polymeropoulos MH (2009) Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol Psychiatry 14:804-819
138. Le Pen G, Grottick AJ, Higgins GA, Moreau JL (2003) Phencyclidine exacerbates attentional deficits in a neurodevelopmental rat model of schizophrenia. Neuropsychopharmacology 28:1799-1809
139. Leliveld SR, Bader V, Hendriks P, Prikulis I, Sajnani G, Requena JR, Korth C (2008) Insolubility of disrupted-in-schizophrenia 1 disrupts oligomer-dependent interactions with nuclear distribution element 1 and is associated with sporadic mental disease. J Neurosci 28:3839-3845
140. Levin ED, Petro A, Beatty A (2005) Olanzapine interactions with nicotine and mecamylamine in rats: effects on memory function. Neurotoxicol Teratol 27:459-464
141. Levin ED, Petro A, Rezvani AH, Pollard N, Christopher NC, Strauss M, Avery J, Nicholson J, Rose JE (2009) Nicotinic alpha7-or beta2-containing receptor knockout: effects on radial-arm maze learning and long-term nicotine consumption in mice. Behav Brain Res 196:207-213
142. Lewandowski KE (2007) Relationship of catechol-O-methyltransferase to schizophrenia and its correlates: evidence for associations and complex interactions. Harv Rev Psychiatry 15:233-244
143. Li W, Zhang Q, Oiso N, Novak EK, Gautam R, O'Brien EP, Tinsley CL, Blake DJ, Spritz RA, Copeland NG, Jenkins NA, Amato D, Roe BA, Starcevic M, Dell'Angelica EC, Elliott RW, Mishra V, Kingsmore SF, Paylor RE, Swank RT (2003) Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). Nat Genet 35:84-89
144. Li W, Zhou Y, Jentsch JD, Brown RA, Tian X, Ehninger D, Hennah W, Peltonen L, Lonnqvist J, Huttunen MO, Kaprio J, Trachtenberg JT, Silva AJ, Cannon TD (2007) Specific developmental disruption of disrupted-in-schizophrenia-1 function results in schizophrenia-related phenotypes in mice. Proc Natl Acad Sci USA 104:18280-18285
145. Lieberman JA, Sheitman BB, Kinon BJ (1997) Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 17:205-229
146. Lipska BK, Weinberger DR (1995) Genetic variation in vulnerability to the behavioral effects of neonatal hippocampal damage in rats. Proc Natl Acad Sci USA 92:8906-8910
147. Lipska BK, Weinberger DR (2000) To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23:223-239
148. Lipska BK, Swerdlow NR, Geyer MA, Jaskiw GE, Braff DL, Weinberger DR (1995) Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology (Berl) 122:35-43
149. Liu CM, Hwu HG, Lin MW, Ou-Yang WC, Lee SF, Fann CS, Wong SH, Hsieh SH (2001) Suggestive evidence for linkage of schizophrenia to markers at chromosome 15q13-14 in Taiwanese families. Am J Med Genet 105:658-661
150. Lu L, Mamiya T, Lu P, Toriumi K, Mouri A, Hiramatsu M, Kim HC, Zou LB, Nagai T, Nabeshima T (2009) Prenatal exposure to phencyclidine produces abnormal behaviour and NMDA receptor expression in postpubertal mice. Int J Neuropsychopharmacol 19:1-13
151. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R (1959) Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry 81:363-369
152. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A (1996) NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14:301-307
153. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, Breier A (1997) Ketamineinduced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17:141-150
154. Marder SR, Fenton W (2004) Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res 72:5-9
155. Martin LF, Kem WR, Freedman R (2004) Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology (Berl) 174:54-64
156. Martinez V, Sarter M (2008) Detection of the moderately beneficial cognitive effects of low-dose treatment with haloperidol or clozapine in an animal model of the attentional impairments of schizophrenia. Neuropsychopharmacology 33:2635-2647
157. Matthysse S (1986) Animal models in psychiatric research. Prog Brain Res 65:259-270
158. McGaughy J, Sarter M (1995) Behavioral vigilance in rats: task validation and effects of age, amphetamine, and benzodiazepine receptor ligands. Psychopharmacology (Berl) 117:340-357
159. McGaughy J, Kaiser T, Sarter M (1996) Behavioral vigilance following infusions of 192 IgGsaporin into the basal forebrain: selectivity of the behavioral impairment and relation to cortical AChE-positive fiber density. Behav Neurosci 110:247-265
160. Metzger KL, Maxwell CR, Liang Y, Siegel SJ (2007) Effects of nicotine vary across two auditory evoked potentials in the mouse. Biol Psychiatry 61:23-30
161. Millar JK, Wilson-Annan JC, Anderson S, Christie S, Taylor MS, Semple CA, Devon RS, St Clair DM, Muir WJ, Blackwood DH, Porteous DJ (2000) Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet 9:1415-1423
162. Millar JK, Christie S, Anderson S, Lawson D, Hsiao-Wei Loh D, Devon RS, Arveiler B, Muir WJ, Blackwood DH, Porteous DJ (2001) Genomic structure and localisation within a linkage hotspot of disrupted in schizophrenia 1, a gene disrupted by a translocation segregating with schizophrenia. Mol Psychiatry 6:173-178
163. Minassian A, Henry BL, Geyer MA, Paulus MP, Young JW, Perry W (2009) The quantitative assessment of motor activity in mania and schizophrenia. J Affect Disord 120:200-206
164. Miner LA, Ostrander M, Sarter M (1997) Effects of ibotenic acid-induced loss of neurons in the medial prefrontal cortex of rats on behavioral vigilance: evidence for executive dysfunction. J Psychopharmacol 11:169-178
165. Moghaddam B, Adams BW (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281:1349-1352
166. Moreno JL, Sealfon SC, Gonzalez-Maeso J (2009) Group II metabotropic glutamate receptors and schizophrenia. Cell Mol Life Sci 66:3777-3785
167. Morris RGM (1981) Spatial localization does not require the presence of local cues. Learn Motiv 12:239
168. Moser PC, Hitchcock JM, Lister S, Moran PM (2000) The pharmacology of latent inhibition as an animal model of schizophrenia. Brain Res Brain Res Rev 33:275-307
169. Muir JL, Dunnett SB, Robbins TW, Everitt BJ (1992) Attentional functions of the forebrain cholinergic systems: effects of intraventricular hemicholinium, physostigmine, basal forebrain lesions and intracortical grafts on a multiple-choice serial reaction time task. Exp Brain Res 89:611-622
170. Muir WJ, Pickard BS, Blackwood DH (2008) Disrupted-in-schizophrenia-1. Curr Psychiatry Rep 10:140-147
171. Murphy KC, Jones LA, Owen MJ (1999) High rates of schizophrenia in adults with velo-cardiofacial syndrome. Arch Gen Psychiatry 56:940-945
172. Mutsuddi M, Morris DW, Waggoner SG, Daly MJ, Scolnick EM, Sklar P (2006) Analysis of highresolution HapMap of DTNBP1 (Dysbindin) suggests no consistency between reported common variant associations and schizophrenia. Am J Hum Genet 79:903-909
173. Ngan ET, Yatham LN, Ruth TJ, Liddle PF (2000) Decreased serotonin 2A receptor densities in neuroleptic-naive patients with schizophrenia: A PET study using [(18)F]setoperone. Am J Psychiatry 157:1016-1018
174. Nieuwenstein MR, Aleman A, de Haan EH (2001) Relationship between symptom dimensions and neurocognitive functioning in schizophrenia: a meta-analysis of WCST and CPT studies. Wisconsin Card Sorting Test. Continuous Performance Test. J Psychiatr Res 35:119-125
175. Nikiforuk A, Golembiowska K, Popik P (2010) Mazindol attenuates ketamine-induced cognitive deficit in the attentional set shifting task in rats. Eur Neuropsychopharmacol 20:37-48
176. Norton N, Williams HJ, Owen MJ (2006) An update on the genetics of schizophrenia. Curr Opin Psychiatry 19:158-164
177. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK (2004) Identification of separable cognitive factors in schizophrenia. Schizophr Res 72:29-39
178. Nuechterlein KH, Luck SJ, Lustig C, Sarter M (2009) CNTRICS final task selection: control of attention. Schizophr Bull 35:182-196
179. O'Tuathaigh CM, O'Connor AM, O'Sullivan GJ, Lai D, Harvey R, Croke DT, Waddington JL (2008) Disruption to social dyadic interactions but not emotional/anxiety-related behaviour in mice with heterozygous 'knockout' of the schizophrenia risk gene neuregulin-1. Prog Neuropsychopharmacol Biol Psychiatry 32:462-466
180. Olds J, Milner P (1954) Positive reinforcement produced by electrical stimulation of septal area and other region of rat brain. J Comp Physiol Psychol 47:419-427
181. Olton DS, Werz MA (1978) Hippocampal function and behavior: spatial discrimination and response inhibition. Physiol Behav 20:597-605
182. Orr-Urtreger A, Goldner FM, Saeki M, Lorenzo I, Goldberg L, De Biasi M, Dani JA, Patrick JW, Beaudet AL (1997) Mice deficient in the alpha7 neuronal nicotinic acetylcholine receptor lack alpha-bungarotoxin binding sites and hippocampal fast nicotinic currents. J Neurosci 17:9165-9171
183. Owen AM, Roberts AC, Polkey CE, Sahakian BJ, Robbins TW (1991) Extra-dimensional versus intra-dimensional set shifting performance following frontal lobe excisions, temporal lobe excisions or amygdalo-hippocampectomy in man. Neuropsychologia 29:993-1006
184. Pantelis C, Barber FZ, Barnes TR, Nelson HE, Owen AM, Robbins TW (1999) Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage. Schizophr Res 37:251-270
185. Paterlini M, Zakharenko SS, Lai WS, Qin J, Zhang H, Mukai J, Westphal KG, Olivier B, Sulzer D, Pavlidis P, Siegelbaum SA, Karayiorgou M, Gogos JA (2005) Transcriptional and behavioral interaction between 22q11.2 orthologs modulates schizophrenia-related phenotypes in mice. Nat Neurosci 8:1586-1594
186. Pattij T, Janssen MC, Loos M, Smit AB, Schoffelmeer AN, van Gaalen MM (2007) Strain specificity and cholinergic modulation of visuospatial attention in three inbred mouse strains. Genes Brain Behav 6:579-587
187. Paylor R, Nguyen M, Crawley JN, Patrick J, Beaudet A, Orr-Urtreger A (1998) Alpha7 nicotinic receptor subunits are not necessary for hippocampal-dependent learning or sensorimotor gating: a behavioral characterization of Acra7-deficient mice. Learn Mem 5:302-316
188. Pearlson GD (2000) Neurobiology of schizophrenia. Ann Neurol 48:556-566
189. Perry W, Minassian A, Paulus MP, Young JW, Kincaid MJ, Ferguson EJ, Henry BL, Masten VL, Sharp RF, Geyer MA (2009) A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men. Arch Gen Psychiatry 60:1072-1080
190. Peters K, Wiltshire S, Henders AK, Dragovic M, Badcock JC, Chandler D, Howell S, Ellis C, Bouwer S, Montgomery GW, Palmer LJ, Kalaydjieva L, Jablensky A (2008) Comprehensive analysis of tagging sequence variants in DTNBP1 shows no association with schizophrenia or with its composite neurocognitive endophenotypes. Am J Med Genet B Neuropsychiatr Genet 147B:1159-1166
191. Petryshen TL, Middleton FA, Kirby A, Aldinger KA, Purcell S, Tahl AR, Morley CP, McGann L, Gentile KL, Rockwell GN, Medeiros HM, Carvalho C, Macedo A, Dourado A, Valente J, Ferreira CP, Patterson NJ, Azevedo MH, Daly MJ, Pato CN, Pato MT, Sklar P (2005) Support for involvement of neuregulin 1 in schizophrenia pathophysiology. Mol Psychiatry 10(366-374):328
192. Pickard BS, Malloy MP, Porteous DJ, Blackwood DH, Muir WJ (2005) Disruption of a brain transcription factor, NPAS3, is associated with schizophrenia and learning disability. Am J Med Genet B Neuropsychiatr Genet 136B:26-32
193. Pickard BS, Christoforou A, Thomson PA, Fawkes A, Evans KL, Morris SW, Porteous DJ, Blackwood DH, Muir WJ (2009) Interacting haplotypes at the NPAS3 locus alter risk of schizophrenia and bipolar disorder. Mol Psychiatry 14:874-884
194. Pletnikov MV, Ayhan Y, Nikolskaia O, Xu Y, Ovanesov MV, Huang H, Mori S, Moran TH, Ross CA (2008) Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia. Mol Psychiatry 13(173-186):115
195. Porteous DJ, Thomson P, Brandon NJ, Millar JK (2006) The genetics and biology of DISC1-an emerging role in psychosis and cognition. Biol Psychiatry 60:123-131
196. Powell SB (2010) Models of neurodevelopmental abnormalities in schizophrenia. Curr Top Behav Neurosci. doi: 10.1007/7854_2010_57
197. Powell SB, Zhou X, Geyer MA (2009) Prepulse inhibition and genetic mouse models of schizophrenia. Behav Brain Res 204:282-294
198. Qian Q, Wang Y, Zhou R, Li J, Wang B, Glatt S, Faraone SV (2003) Family-based and casecontrol association studies of catechol-O-methyltransferase in attention deficit hyperactivity disorder suggest genetic sexual dimorphism. Am J Med Genet B Neuropsychiatr Genet 118B:103-109
199. Risbrough VB, Masten VL, Caldwell S, Paulus MP, Low MJ, Geyer MA (2006) Differential contributions of dopamine D(1), D(2), and D(3) receptors to MDMA-induced effects on locomotor behavior patterns in mice. Neuropsychopharmacology 31:2349-2358
200. Robbins TW, Everitt BJ, Marston HM, Wilkinson J, Jones GH, Page KJ (1989) Comparative effects of ibotenic acid-and quisqualic acid-induced lesions of the substantia innominata on attentional function in the rat: further implications for the role of the cholinergic neurons of the nucleus basalis in cognitive processes. Behav Brain Res 35:221-240
201. Russig H, Durrer A, Yee BK, Murphy CA, Feldon J (2003) The acquisition, retention and reversal of spatial learning in the morris water maze task following withdrawal from an escalating dosage schedule of amphetamine in wistar rats. Neuroscience 119:167-179
202. Rutten K, Reneerkens OA, Hamers H, Sik A, McGregor IS, Prickaerts J, Blokland A (2008) Automated scoring of novel object recognition in rats. J Neurosci Methods 171:72-77
203. Sambeth A, Riedel WJ, Smits LT, Blokland A (2007) Cholinergic drugs affect novel object recognition in rats: relation with hippocampal EEG? Eur J Pharmacol 572:151-159
204. Sams-Dodd F (1999) Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity. Rev Neurosci 10:59-90
205. Sams-Dodd F (2004) (+) MK-801 and phencyclidine induced neurotoxicity do not cause enduring behaviours resembling the positive and negative symptoms of schizophrenia in the rat. Basic Clin Pharmacol Toxicol 95:241-246
206. Sanders AR, Duan J, Levinson DF, Shi J, He D, Hou C, Burrell GJ, Rice JP, Nertney DA, Olincy A, Rozic P, Vinogradov S, Buccola NG, Mowry BJ, Freedman R, Amin F, Black DW, Silverman JM, Byerley WF, Crowe RR, Cloninger CR, Martinez M, Gejman PV (2008) No significant association of 14 candidate genes with schizophrenia in a large European ancestry sample: implications for psychiatric genetics. Am J Psychiatry 165:497-506
207. Sarter M, Martinez V, Kozak R (2009) A neurocognitive animal model dissociating between acute illness and remission periods of schizophrenia. Psychopharmacology (Berl) 202:237-258
208. Sawamura N, Sawa A (2006) Disrupted-in-schizophrenia-1 (DISC1): a key susceptibility factor for major mental illnesses. Ann N Y Acad Sci 1086:126-133
209. Scarr E, Dean B (2008) Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia? J Neurochem 107:1188-1195
210. Schwab SG, Knapp M, Mondabon S, Hallmayer J, Borrmann-Hassenbach M, Albus M, Lerer B, Rietschel M, Trixler M, Maier W, Wildenauer DB (2003) Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. Am J Hum Genet 72:185-190
211. Seeman P, Guan HC (2008) Phencyclidine and glutamate agonist LY379268 stimulate dopamine D2High receptors: D2 basis for schizophrenia. Synapse 62:819-828
212. Seeman P, Lee T, Chau-Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptic/ dopamine receptors. Nature 261:717-719
213. Segal DS, Geyer MA (1985) Animal models of psychopathology. In: Judd LL, Groves PM (eds) Psychobiological foundations of clinical psychiatry. J.B. Lippincott Co., Philadelphia
214. Shannon HE, Peters SC (1990) A comparison of the effects of cholinergic and dopaminergic agents on scopolamine-induced hyperactivity in mice. J Pharmacol Exp Ther 255:549-553
215. Shashi V, Keshavan MS, Howard TD, Berry MN, Basehore MJ, Lewandowski E, Kwapil TR (2006) Cognitive correlates of a functional COMT polymorphism in children with 22q11.2 deletion syndrome. Clin Genet 69:234-238
216. Shoblock JR, Maisonneuve IM, Glick SD (2003) Differences between d-methamphetamine and d-amphetamine in rats: working memory, tolerance, and extinction. Psychopharmacology (Berl) 170:150-156
217. Slifstein M, Kolachana B, Simpson EH, Tabares P, Cheng B, Duvall M, Gordon Frankle W, Weinberger DR, Laruelle M, Abi-Dargham A (2008) COMT genotype predicts cortical-limbic D1 receptor availability measured with [(11)C]NNC112 and PET. Mol Psychiatry 13:821-827
218. Snigdha S, Neill JC (2008) Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats-a preliminary investigation. Behav Brain Res 187:489-494
219. Stark KL, Burt RA, Gogos JA, Karayiorgou M (2009) Analysis of prepulse inhibition in mouse lines overexpressing 22q11.2 orthologues. Int J Neuropsychopharmacol 11:1-7
220. Stefani MR, Moghaddam B (2002) Effects of repeated treatment with amphetamine or phencyclidine on working memory in the rat. Behav Brain Res 134:267-274
221. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, Brynjolfsson J, Gunnarsdottir S, Ivarsson O, Chou TT, Hjaltason O, Birgisdottir B, Jonsson H, Gudnadottir VG, Gudmundsdottir E, Bjornsson A, Ingvarsson B, Ingason A, Sigfusson S, Hardardottir H, Harvey RP, Lai D, Zhou M, Brunner D, Mutel V, Gonzalo A, Lemke G, Sainz J, Johannesson G, Andresson T, Gudbjartsson D, Manolescu A, Frigge ML, Gurney ME, Kong A, Gulcher JR, Petursson H, Stefansson K (2002) Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 71:877-892
222. Stefansson H, Rujescu D, Cichon S, Pietilainen OP, Ingason A, Steinberg S, Fossdal R, Sigurdsson E, Sigmundsson T, Buizer-Voskamp JE, Hansen T, Jakobsen KD, Muglia P, Francks C, Matthews PM, Gylfason A, Halldorsson BV, Gudbjartsson D, Thorgeirsson TE, Sigurdsson A, Jonasdottir A, Bjornsson A, Mattiasdottir S, Blondal T, Haraldsson M, Magnusdottir BB, Giegling I, Moller HJ, Hartmann A, Shianna KV, Ge D, Need AC, Crombie C, Fraser G, Walker N, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Paunio T, Toulopoulou T, Bramon E, Di Forti M, Murray R, Ruggeri M, Vassos E, Tosato S, Walshe M, Li T, Vasilescu C, Muhleisen TW, Wang AG, Ullum H, Djurovic S, Melle I, Olesen J, Kiemeney LA, Franke B, Sabatti C, Freimer NB, Gulcher JR, Thorsteinsdottir U, Kong A, Andreassen OA, Ophoff RA, Georgi A, Rietschel M, Werge T, Petursson H, Goldstein DB, Nothen MM, Peltonen L, Collier DA, St Clair D, Stefansson K (2008) Large recurrent microdeletions associated with schizophrenia. Nature 455:232-236
223. Stevens KE, Freedman R, Collins AC, Hall M, Leonard S, Marks MJ, Rose GM (1996) Genetic correlation of inhibitory gating of hippocampal auditory evoked response and alpha-bungarotoxin-binding nicotinic cholinergic receptors in inbred mouse strains. Neuropsychopharmacology 15:152-162
224. Stip E, Sepehry AA, Chouinard S (2007) Add-on therapy with acetylcholinesterase inhibitors for memory dysfunction in schizophrenia: a systematic quantitative review, part 2. Clin Neuropharmacol 30:218-229
225. Straub RE, Jiang Y, MacLean CJ, Ma Y, Webb BT, Myakishev MV, Harris-Kerr C, Wormley B, Sadek H, Kadambi B, Cesare AJ, Gibberman A, Wang X, O'Neill FA, Walsh D, Kendler KS (2002) Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genet 71:337-348
226. Sullivan PF (2008) The dice are rolling for schizophrenia genetics. Psychol Med 38:1693-1696, discussion 1818-1820
227. Suzuki G, Harper KM, Hiramoto T, Funke B, Lee M, Kang G, Buell M, Geyer MA, Kucherlapati R, Morrow B, Mannisto PT, Agatsuma S, Hiroi N (2009) Over-expression of a human chromosome 22q11.2 segment including TXNRD2, COMT and ARVCF developmentally affects incentive learning and working memory in mice. Hum Mol Genet 18:3914-3925
228. Swerdlow NR (2010) A cautionary note about latent inhibition in schizophrenia: Are we ignoring relevant information. In: Lubow RE, Weiner I (eds) Latent inhibition: cognition, neuroscience, and applications to schizophrenia. Cambridge University Press, Cambridge, pp 448-456
229. Swerdlow NR, Geyer MA (1998) Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr Bull 24:285-301
230. Swerdlow NR, Braff DL, Taaid N, Geyer MA (1994) Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 51:139-154
231. Swerdlow NR, Braff DL, Hartston H, Perry W, GeyerMA (1996) Latent inhibition in schizophrenia. Schizophr Res 20:91-103
232. Swerdlow NR, Bakshi V, Waikar M, Taaid N, Geyer MA (1998) Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats. Psychopharmacology (Berl) 140:75-80
233. Swerdlow NR, Weber M, Qu Y, Light GA, Braff DL (2008) Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology (Berl) 199:331-388
234. Taiminen T, Jaaskelainen S, Ilonen T, Meyer H, Karlsson H, Lauerma H, Leinonen KM, Wallenius E, Kaljonen A, Salokangas RK (2000) Habituation of the blink reflex in first-episode schizophrenia, psychotic depression and non-psychotic depression. Schizophr Res 44:69-79
235. Tait DS, Marston HM, Shahid M, Brown VJ (2009) Asenapine restores cognitive flexibility in rats with medial prefrontal cortex lesions. Psychopharmacology (Berl) 202:295-306
236. Takao K, Miyakawa T (2008) Investigating genes-to-behavior pathways in psychiatric diseases: an approach using a comprehensive behavioral test battery on genetically engineered mice. Nihon Shinkei Seishin Yakurigaku Zasshi 28:135-142
237. Tamminga CA (1998) Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol 12:21-36
238. Thompson JL, Watson JR, Steinhauer SR, Goldstein G, Pogue-Geile MF (2005) Indicators of genetic liability to schizophrenia: a sibling study of neuropsychological performance. Schizophr Bull 31:85-96
239. Tsuang M (2000) Schizophrenia: genes and environment. Biol Psychiatry 47:210-220
240. Turgeon SM, Hulick VC (2007) Differential effects of acute and subchronic clozapine and haloperidol on phencyclidine-induced decreases in voluntary sucrose consumption in rats. Pharmacol Biochem Behav 86:524-530
241. Umbricht D, Vyssotky D, Latanov A, Nitsch R, Brambilla R, D'Adamo P, Lipp HP (2004) Midlatency auditory event-related potentials in mice: comparison to midlatency auditory ERPs in humans. Brain Res 1019:189-200
242. van Os J, McGuffin P (2003) Can the social environment cause schizophrenia? Br J Psychiatry 182:291-292
243. Waters KA, Burnham KE, O'Connor D, Dawson GR, Dias R (2005) Assessment of modafinil on attentional processes in a five-choice serial reaction time test in the rat. J Psychopharmacol 19:149-158
244. Weiner I, Gal G, Rawlins JN, Feldon J (1996) Differential involvement of the shell and core subterritories of the nucleus accumbens in latent inhibition and amphetamine-induced activity. Behav Brain Res 81:123-133
245. Wiley JL, Compton AD (2004) Progressive ratio performance following challenge with antipsychotics, amphetamine, or NMDA antagonists in adult rats treated perinatally with phencyclidine. Psychopharmacology (Berl) 177:170-177
246. Williams HJ, Owen MJ, O'Donovan MC (2007) Is COMT a susceptibility gene for schizophrenia? Schizophr Bull 33:635-641
247. Williams HJ, Owen MJ, O'Donovan MC (2009) Schizophrenia genetics: new insights from new approaches. Br Med Bull 91:61-74
248. Wittmann M, Carter O, Hasler F, Cahn BR, Grimberg U, Spring P, Hell D, Flohr H, Vollenweider FX (2007) Effects of psilocybin on time perception and temporal control of behaviour in humans. J Psychopharmacol 21:50-64
249. Wolpowitz D, Mason TB, Dietrich P, Mendelsohn M, Talmage DA, Role LW (2000) Cysteinerich domain isoforms of the neuregulin-1 gene are required for maintenance of peripheral synapses. Neuron 25:79-91
250. Wyvell CL, Berridge KC (2001) Incentive sensitization by previous amphetamine exposure: increased cue-triggered "wanting" for sucrose reward. J Neurosci 21:7831-7840
251. Young JW, Finlayson K, Spratt C, Marston HM, Crawford N, Kelly JS, Sharkey J (2004) Nicotine improves sustained attention in mice: evidence for involvement of the alpha7 nicotinic acetylcholine receptor. Neuropsychopharmacology 29:891-900
252. Young JW, Crawford N, Kelly JS, Kerr LE, Marston HM, Spratt C, Finlayson K, Sharkey J (2007a) Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice. Eur Neuropsychopharmacol 17:145-155
253. Young JW, Geyer MA, subcommittee p (2007b) Report on putative preclinical models of the MATRICS battery. http://www.turns.ucla.edu/preclinical-TURNS-report-2006b.pdf
254. Young JW, Minassian A, Paulus MP, Geyer MA, Perry W (2007c) A reverse-translational approach to bipolar disorder: rodent and human studies in the Behavioral Pattern Monitor. Neurosci Biobehav Rev 31:882-896
255. Young JW, Goey AK, Minassian A, Perry W, Paulus MP, Geyer MA (2009a) GBR 12909 administration as a mouse model of bipolar disorder mania: mimicking quantitative assessment of manic behavior. Psychopharmacology (Berl) 208:443s
256. Young JW, Powell SB, Risbrough V, Marston HM, Geyer MA (2009b) Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther 122:150-202
257. Zhou X, Long JM, Geyer MA, Masliah E, Kelsoe JR, Wynshaw-Boris A, Chien KR (2005) Reduced expression of the Sp4 gene in mice causes deficits in sensorimotor gating and memory associated with hippocampal vacuolization. Mol Psychiatry 10:393-406
258. Zhou X, Qyang Y, Kelsoe JR, Masliah E, Geyer MA (2007) Impaired postnatal development of hippocampal dentate gyrus in Sp4 null mutant mice. Genes Brain Behav 6:269-276
259. Zhou X, Geyer MA, Kelsoe JR (2008) Does disrupted-in-schizophrenia (DISC1) generate fusion transcripts? Mol Psychiatry 13:361-363
260. Zhou X, Tang W, Greenwood TA, Guo S, He L, Geyer MA, Kelsoe JR (2009) Transcription factor SP4 is a susceptibility gene for bipolar disorder. PLoS ONE 4:e5196